() experienced a significant increase in short interest during the month of April. On April 30, there were 1,350,000 short shares. This is a 22.7% increase from the total of 1,100,000.000 shares on April 15. The days-to-cover is 9.8 days based on an average daily volume of 137.100 shares.
Analyst Ratings Changes
RVPH was the subject of several research reports. Maxim Group raised their target price for Reviva Pharmaceuticals in a report published on Wednesday, 3rd May from $10.00 up to $18.00. Recently, several hedge funds and institutional investors bought and sold the stock. Tang Capital Management LLC purchased a new position worth $103,000 in Reviva Pharmaceuticals at the end of the fourth quarter. Two Sigma Investments LP purchased a new Reviva Pharmaceuticals position during the fourth quarter, worth about $200,000. Charles Schwab Investment Management Inc. purchased a new position worth $52,000 in Reviva Pharmaceuticals. Renaissance Technologies LLC purchased a new Reviva Pharmaceuticals position during the fourth quarter, valued at approximately $86,000. Geode Capital Management LLC increased its holdings in Reviva Pharmaceuticals shares by 86.3% during the fourth quarter. Geode Capital Management LLC owns 145.430 shares worth $618,000, after buying an additional 67.355 shares during the last quarter. Institutional investors and hedge fund own 10.29%.
Reviva Pharmaceuticals Price Performance
Trading at midday on Friday saw a decline of $0.58, bringing the price to $7.34. The company's average trading volume is 138,807. 204,854 of its shares were traded, compared with 138,807. The fifty-day moving price of the company is $5.39, and its 200 day moving price is $4.65. The market cap is $150.12m, the PE ratio is -5.87, and beta 0.12. Reviva Pharmaceuticals' 52-week low is $0.53, and its 52-week high is $9.25.
Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical firm in clinical stages that specializes in discovering and developing therapeutics to treat central nervous system, respiratory, metabolic and other diseases. The company uses a chemical genomics-driven technology platform, as well as proprietary chemistry, to develop new drugs.
MarketBeat.com offers a FREE daily email newsletter